FindTrial
Sign In

Studying the role of a blood vessel marker (CD34) in understanding how bowel cancer behaves and spreads.

Assessing the utility of CD34 expression as an immunohistochemical histopathological marker for tumour behavior in comparison to histopathological parameters and tumour,lymph node and metastatic staging in colorectal carcinoma - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/02/102739
Enrollment
50
Registered
2026-02-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C18- Malignant neoplasm of colon Health Condition 2: C20- Malignant neoplasm of rectum

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Manya Puri
Lead Sponsor
Pathologist
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.Already diagnosed as Colorectal carcinoma on histopathology. 2.All cases with colectomy /hemicolectomy/ abdominoperineal resection with suitable lymph node dissection. 3.Primary cases of Colorectal carcinoma without any history of previous treatment. 4.All patients with Colorectal carcinoma arising de novo.

Exclusion criteria

Exclusion criteria: 1.All benign lesions of colon and rectum and other malignant carcinomas like neuroendocrine tumors and gastrointestinal stromal tumor 2.All the already treated cases of Colorectal Carcinoma. 3.All patients with Colorectal carcinoma where the cancer is arising as a result of recurrence. 4.All patients who have defaulted treatment. 5.Patients with no histological confirmation of Colorectal Carcinoma.

Design outcomes

Primary

MeasureTime frame
The study demonstrates that CD34 expression, as a marker of microvessel density (angiogenesis), shows a significant correlation with tumor aggressiveness in colorectal carcinoma.Timepoint: 24 hours—

Secondary

MeasureTime frame
nilTimepoint: nil—

Countries

India

Contacts

Public ContactDr Samarth Shukla

JNMC , Wardha

samarth21174@gmail.com8830267710

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026